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Objective: To evaluate whether epilepsy or certain antiepileptic drugs render patients prone
to develop low bone mineral density (BMD) and osteoporosis risk.
Methods: Thirty-eight (27 males, 11 females) consecutive adult epileptic patients receiving
antiepileptic drugs (AEDs) and 71 control individuals matched for race, gender, age and body
mass index (BMI) were subjected to dual energy X-ray absorptiometry (DXA).
Results: The mean lumbar spine and total hip BMD values were lower in the patients
compared to control group (0.90  0.24 g/cm2 vs 1.04  0.14 g/cm2, p < 0.001 and 0.92
 0.14 g/cm2 vs 0.99  0.13 g/cm2, p = 0.02, respectively). At the same skeletal sites, male
patients had signiﬁcantly reduced BMD compared to control males (0.90  0.21 g/cm2 vs 1.03
 0.15 g/cm2, p = 0.004 and 0.93  0.14 g/cm2 vs 1.02  0.13 g/cm2, p = 0.009, respectively)
while there was a trend but no signiﬁcant differences in females. This BMD reduction
was independent of AED type.
Conclusion: Adult epileptic, predominantly male patients have lower BMD and could be
screened with densitometry for early diagnosis and prevention of osteoporosis.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Low bone mineral density (BMD) is rare in young adults and
either occurs in pregnant females as transient osteoporosis
[1,2] or in both sexes in certain diseases such as multiple* Corresponding author at: Department of Nuclear Medicine, Universit
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0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Ssclerosis [3,4], chronic glucocorticoid administration or immo-
bility [4], stroke [5], and epilepsy [6,7].
Epileptic patients may exhibit low BMD possibly as a side
effect of certain antiepileptic drugs (AEDs) use, even in
children below 18 years old [6]. AEDs can be categorized into
three broad groups in accordance to their property to induce,y Hospital of Ioannina, 1 Stavrou Niarchou Street, Ioannina 45500,
ahoo.com (C. Sioka), texarnuc@yahoo.gr (T. Exarchopoulos),
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p. z o.o. All rights reserved.
Table 1 – Characteristics of the patients and control group
individuals.
Characteristics Patients (38) Controls (71) p
Gender 27 M/11 F 49 M/22 F 0.82
Mean age, years 38.2  12.3 38.9  10.4 0.74
Males 39.04  13.4 40.08  10.7 0.71
Females 36.1  8.9 36.3  9.3 0.94
BMI (kg/m2) 26.01  4.8 26.1  3.7 0.85
Males 26.2  4.7 27.1  3.2 0.25
Females 25.7  5.3 23.9  3.9 0.27
Smoking (%) 14 (36.8%) 44 (61%) 0.01
Males 11 (40.7%) 30 (61.2%) 0.07
Females 3 (27.2%) 14 (63.6%) 0.05
Median E duration,
years (range)
10 (1–40)
Males 12 (1–40)
Females 6 (1–35)
M: males; F: females; E: epilepsy; BMI: body mass index; BMD: bone
mineral density.
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cytochrome P450 2C19 (CYP2C19), that metabolize various
drugs, including clopidogrel and several AEDs: the ﬁrst group
includes the enzyme inducers, such as carbamazepine,
phenobarbital, phenytoin, and primidone, the second group
consists of the enzyme inhibitor VPA, and the third group
consists of enzyme non-inducers/inhibitors such as clonaze-
pam, ethosuximide, gabapentin, lacosamide, lamotrigine,
pregabalin, tiagabine, and zonisamide. It has been suggested
that the AEDs with hepatic enzyme induction properties may
exercise a negative effect on BMD in comparison to non-
inducer AEDs. Furthermore, valproate may negatively inﬂu-
ence BMD [8]. Thus, valproic acid monotherapy may be a cause
for low BMD in epileptic patients according to Sato et al. [9];
however, Triantafyllou et al. did not observe any relation of
long term valproate monotherapy with reduced BMD [10].
There have been controversial studies concerning gender,
with either reporting lower BMD in epileptic males than
females, or equally reduced BMD in both gender [7,11,12]. In
any event, the associations of gender and AEDs with BMD are
still unresolved in epilepsy and deserve further investigation
[10,13]. The objective of the present case–control study was to
evaluate the BMD at certain skeletal sites of adult epileptic
patients and its potential association with gender and AED
type.
2. Patients and methods
2.1. Participants
Thirty-eight (27 males, 11 females) adult epileptic patients on
various AEDs and 71 race, gender, age and BMI matched
controls were subjected to DXA scanning. Epileptic patients
were adults, receiving AEDs for more than 1 year, as described
below. Patient data, including gender and age, body mass
index (BMI), length of exposure to AEDs and AEDs type, were
recorded. The control group included 71 healthy non-relative
visitors to hospitalized patients. Smoking, either active or
ceased within the last 6 months, was recorded as current for all
participants and BMI was calculated. Participants with BMI
higher than 40 kg/m2, on corticosteroids, bisphosphonates or
selective estrogen receptor modulators use and/or with a
medical condition or metallic implants, that inﬂuence DXA
values, were excluded.
According to the number and type of AEDs administrated,
patients were further sub-grouped: Group A includedpatients on
AEDs with either weak or no CYP2C19 inducing or inhibiting
properties (lamotrigine, levetiracetam, oxcarbamazepine,
tomiramate or/and gabapentin); Group B included patients on
AEDs with CYP2C19 inducing properties, as phenytoin (PHT),
carbamazepine(CBZ) and/or phenobarbital (PB)onmonotherapy
or polytherapy; Group C includedpatients receiving valproic acid
(VPA), a known CYP2C19 inhibitor, with or without concurrent
AEDs having no inducing or inhibiting properties; Group D
included patients taking or having taken a combination of AEDs
with enzyme-inducing properties (CBZ, PHT, PB) and VPA.
The study protocol was in compliance with the Helsinki
Declaration and an informed consent was signed by all
participants.2.2. Scanning
DXA scanning was performed utilizing a Hologic Discovery W
scanner (Hologic, Bedford, MA, USA). All patients had DXA
scans performed in the supine position, in both the lumbar
spine (L1–L4) and left hip. The scans and data analysis were
performed by the same technician. For data analysis, a
software package (v.12.3:7; Hologic, Bedford, MA, USA) was
employed as directed by the manufacturer.
2.3. Statistical analysis
Multivariate regression analysis was performed after adjust-
ment for gender, age, BMI, smoking, length of exposure to AEDs
and AEDs type. For statistical analysis, epileptic patients were
studied in four subgroups according to their AEDs as mentioned
above. Statistical analysis was undertaken using SPSS 20.0 for
windows. P values less than 0.05 were considered signiﬁcant.
3. Results
Thirty-eight ambulatory adult outpatients (27 males, 11 females)
with epilepsy were recruited in the study. Patients and control
group physical characteristics are depicted in Table 1.
The mean lumbar spine and total hip BMD values were
signiﬁcantly lower in the patient group than the control group
(0.90  0.24 g/cm2 versus 1.04  0.14 g/cm2, p < 0.001 and 0.92
 0.14 g/cm2 versus 0.99  0.13 g/cm2, p = 0.02, respectively)
while no statistically signiﬁcant difference was found for
femoral neck BMD (Table 2).
Age, BMI and smoking were signiﬁcantly associated with
every mean BMD value. Further multivariate regression
analysis with adjustment for age, BMI and smoking showed
that lumbar spine mean BMD, but not total hip mean BMD,
was signiﬁcantly decreased ( p = 0.001) in the patient com-
pared to control group. Epilepsy duration was not signiﬁcantly
associated with any of the mean BMD values in the patient
group.
Table 2 – Bone mineral density results of the patients and
control group individuals.
DXA results Patients (38) Controls (71) p
Lumbar spine BMD 0.90  0.24 1.04  0.14 <0.001*
Males 0.90  0.21 1.03  0.15 0.004*
Females 0.90  0.32 1.06  0.11 0.052
Total hip BMD 0.92  0.14 0.99  0.13 0.02*
Males 0.93  0.14 1.02  0.13 0.009*
Females 0.92  0.15 0.94  0.14 0.69
Femoral neck BMD 0.81  0.15 0.85  0.13 0.09
Males 0.80  0.16 0.87  0.13 0.06
Females 0.81  0.14 0.82  0.14 0.85
BMD: bone mineral density (mean value  standard deviation);
DXA: X-ray absorptiometry; males: N = 27; females: N = 11.
* Statistically signiﬁcant.
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were signiﬁcantly lower in male patients than male controls
(0.90  0.21 g/cm2 vs 1.03  0.15 g/cm2, p = 0.004 and 0.93
 0.14 g/cm2 versus 1.02  0.13 g/cm2, p = 0.009, respectively)
but no statistical difference was noted in females, except for a
trend for lower BMD only in lumbar spine. No signiﬁcant
difference regarding femoral neck mean BMD was found in
either gender (Table 1).
Further comparisons of lumbar spine, total hip and femoral
neck BMD were conducted in different AED groups. Noteworthy,
the lumbar spine BMD was lower in Group A patients
(lamotrigine, levetiracetam, oxcarbamazepine, tomiramate
and/or gabapentin) with levetiracetam being the most common
AED used on monotherapy or polytherapy (2 and 5 patients
accordingly), while the total hip and femoral neck BMD were
lower in Group B patients, but no difference reached statistical
signiﬁcance (Table 3). Similar results were found in males, with
the lowest BMD noted in the lumbar spine of Group A patients
but not reaching statistical signiﬁcance. Comparisons among
females were not possible due to the small sample size.
4. Discussion
Several neurological diseases have been associated with low
BMD [3,4,14–16,5,17,18]. Among them, epilepsy is a neurologi-
cal condition of interest due to the presence of seizures thatTable 3 – Mean BMD values in epileptic patients in accordance
AED groups Group A Gr
Patients N = 10 N =
Lumbar spine BMD 0.75  0.35 0.86
Total hip BMD 0.93  0.11 0.82
Femoral neck BMD 0.80  0.10 0.74
Males N = 6 N =
Lumbar spine BMD 0.78  0.34 0.91
Total hip BMD 0.96  0.11 0.85
Femoral neck BMD 0.82  0.12 0.78
AEDs: antiepileptic drugs; BMD: bone mineral density; Group A: patien
CYP2C19 inducing or inhibiting properties; Group B: patients on monother
C: patients on valproic acid, a CYP2C19 inhibitor, with or without concurr
on a combination of AEDs with enzyme-inducing properties and VPA.may cause increased frequency of bone fractures in up to 33.9%
of epileptic individuals [19–21]. In 87 epileptic patients on
phenytoin, the 7 years occurrence of non-seizure-related
fractures was six times more frequent compared to normal
population [22]. The peak period of all fractures in epileptic
patients has been reported between 40 and 49 years of age [20].
In accordance with most studies, our results demonstrated
low BMD in epileptic patients, in both lumbar spine and a total
hip. As it was found in our study (Table 2), male preponderance
was reported in other studies of chronic antiepileptic use in
young adult patients and low BMD [7].
In a study from England including 208 institutionalized
patients, bone disease affected mainly young, male patients
[23], while in a young adult study male gender was a risk factor
for low BMD at the spine of epileptic patients [7]. In our study
all but one female were pre-menopausal. The presence of
estrogens during the pre-menopausal period, contributing to
the maintenance of skeletal homeostasis and the apoptotic
death in osteoclasts [24], potentially explain the gender-
related ﬁndings in studies implicating young epileptic adults,
as the present study.
Apart from the diagnosis of epilepsy, the AEDs have been
accused as risk factors for low bone density [25] and fractures
[19,21]. It has been suggested that the mechanism of action of
antiepileptic drugs on BMD is related to reducing vitamin D
levels, altering vitamin D metabolism or a direct effect on bone
cells, although no deﬁnite proof exists for either possibility
[26]. In our study there was no clear differential susceptibility
of epileptic patients to various AEDs since both hepatic
enzyme-inducing and non-inducing AEDs seem to affect
BMD in some tested sites. However, the results were not
statistically signiﬁcant due to the small number in each
category of various drug combinations. Although many
studies suggest that enzyme-inducing AEDs are the only
AED type causing severe BMD decline and increased fracture
risk [27,28] in epileptic patients this is not always conﬁrmed by
other studies. No speciﬁc AED type was associated with
reduced BMD in a study from England with institutionalized
patients [6], whereas there was no evidence that a speciﬁc type
of AED or vitamin D deﬁciency were related to bone loss in
epileptic patients in a study from Thailand [7] and in a cohort
of adult male patients showing bone loss at the hip [29].
Furthermore non-enzyme-inducing antiepileptic drugs were to AEDs type.
oup B Group C Group D
 7 N = 16 N = 5
  0.16 0.97  0.18 1.04  0.10
  0.15 0.97  0.15 0.91  0.11
  0.19 0.84  0.17 0.80  0.12
 6 N = 11 N = 4
  0.12 0.91  0.17 1.04  0.11
  0.14 0.95  0.17 0.93  0.11
  0.18 0.82  0.19 0.79  0.14
ts on monotherapy or polytherapy of AEDs with either weak or no
apy or polytherapy of AEDs with CYP2C19 inducing properties; Group
ent AEDs with no inducing or inhibiting properties; Group D: patients
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sectional study, with levetiracetam being the drug more often
affecting bone density [30]. In experimental models, new
agents, as levetiracetam, have been shown to weaken the
femoral neck suggesting a primary effect on bone quality of the
newer agents [31].
In the present study, smoking was signiﬁcantly more
common among control individuals compared to epileptic
patients (61% versus 36.8%). Smoking is considered a risk
factor for low BMD and increased incidence of hip fracture [32],
even though the exact mechanism of this association remains
obscure but it could be related to the antiestrogenic effect of
smoking [33], more noticeable in the elderly [34]. The fact that
the epileptic patients in our study were less frequently
smokers compared to controls suggests that the actual
differences in BMD found in the present study could be even
larger. Further prospective studies may clarify these ﬁndings
with certainty.
5. Conclusion
We acknowledge the small sample size as a major limitation of
the present study. Despite that, our ﬁndings indicate that
epileptic patients, predominantly males, have lower BMD and
thus are at risk for osteoporosis, compared to control
individuals, independently of the type of the antiepileptic
drug use. Larger studies, predominantly prospective random-
ized, are needed to further establish a role for each antiepi-
leptic drug category on BMD. Screening for BMD with DXA may
be considered in epileptic patients regardless of the prescribed
AEDs.
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